Navigation Links
Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
Date:12/12/2011

signa were given a new treatment while the others continued to receive a therapy that they had been taking for a minimum of two years(1).

During this study, discontinuation due to adverse events (AEs) occurred in 8.9% and 1% for Tasigna- and Gleevec-treated patients, respectively. The majority of these were asymptomatic laboratory adverse events. The most commonly reported AEs in the Tasigna arm were headache (36.6%), rash (23.8%) and pruritus (23.8%), while in the Gleevec arm the most commonly reported AEs were diarrhea (12.6%) and headache (9.7%)(1).

ECGs were measured at baseline (both treatment arms), at day 8 (Tasigna arm only) and at early discontinuation from study treatment (both treatment arms). No patients in the Tasigna treatment arm were reported to have QTc prolongation intervals greater than 480 msec at baseline or at day 8; four patients (4.0%) had reported QTc prolongation intervals greater than 450 msec on day 8. No patients who discontinued early had QTc prolongation intervals greater than 450 msec(1).

ENESTnd study detailsENESTnd is a Phase III randomized, open-label, multicenter trial comparing the efficacy and safety of Tasigna versus Gleevec in adult patients with newly diagnosed Ph+ CML in chronic phase. It is the largest global randomized comparison of two oral therapies ever conducted in newly diagnosed Ph+ CML patients(2).

The study is being conducted at 217 global sites with 846 patients enrolled. Patients were randomized to receive Tasigna 300 mg twice daily (n=282), Tasigna 400 mg twice daily (n=281) or Gleevec 400 mg once daily (n=283). The primary endpoint was major molecular response (MMR) at 12 months; the key secondary endpoint was durable MMR at 24 months (patients having MMR when evaluated at both 12 and 24 months). MMR was defined in this study as 0.1% or less of Bcr-Abl as measured by RQ-PCR. Planned follow-up is for five years. Patients on the Gleevec treatment arm who had suboptimal response or
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , Aug. 4, 2015 BioElectronics Corporation ... ActiPatch® Musculoskeletal Pain Therapy medical devices, announced today ... its ActiPatch 7-day trial device has been published ... Pain Management http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More than ... and submitted an assessment.  Chronic ...
(Date:8/4/2015)... KNOXVILLE, Tenn., Aug. 4, 2015 Second ... million; 30.1% over second quarter of 2014 , Net ... $28.9 million; $51.2 million after adjustments , Diluted net ... , Adjusted EBITDA increased 15.2% to $99.4 million ... increased to a range of 24.0% to 26.0%; Adjusted EBITDA ...
(Date:8/4/2015)... Minn., Aug. 4, 2015 ANI Pharmaceuticals, Inc. ... for the three and six months ended June 30, ... Company will host its earnings conference call this morning, ... other interested parties can join the call by dialing ... Year-to-Date Highlights Include: , Year-to-date net revenues of ...
Breaking Medicine Technology:BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 2Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 3Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 4Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 5Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 6Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 7Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 8Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 9Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 10Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 11Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 12Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 13Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 14Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 15Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 16Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 17Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 18Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 19Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 20Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 21Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 22Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 23Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 24Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 25Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 26Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 27Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 28Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 29Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 30Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 31Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 32Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 33ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 2ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 3
... International Holdings, Inc. (NYSE Amex: BONE ... bone graft material and antimicrobial coatings for medical ... three-year agreement with Novation, a leading health care ... provides Bacterin,s full biologic portfolio, including OsteoSponge®, OsteoSelect® ...
... Fla., May 8, 2012 Grappling with economic uncertainty, ... industry is on the cusp of major changes, said ... opening session of the 2012 GHX Healthcare Supply Chain ... GPOs and distributors gathered this week in Orlando for ...
Cached Medicine Technology:Bacterin International Signs Its Third National GPO Contract with Novation 2Bacterin International Signs Its Third National GPO Contract with Novation 3Bacterin International Signs Its Third National GPO Contract with Novation 4GHX Reveals Roadmap to Stronger Healthcare Community at GHX Healthcare Supply Chain Summit 2GHX Reveals Roadmap to Stronger Healthcare Community at GHX Healthcare Supply Chain Summit 3
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... Many men ... on the subject, Renew Man™ is standing up as a voice of authority for ... of the healthy aging industry with special experience and expertise in the safe and ...
(Date:8/4/2015)... ... ... 24/7 Care At Home , a provider of comprehensive home health ... the U.S. Department of Veteran’s Affairs (VA) has awarded its agency a rating of ... the path to meeting the aspirational goals the VA promotes each year. , ...
(Date:8/4/2015)... Ohio (PRWEB) , ... August 04, 2015 , ... ... have up-to-date immunizations, especially those entering kindergarten. All required immunizations are covered for ... rules, which means that children who aren’t caught up with their immunizations may ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... firms and government entities, today announced that John Munro, a 15-year veteran of ... President of Managed Services Operations. , “I am thrilled to join Discovia at ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... announced that Bruce McCalley joins its executive leadership team as Senior Vice President ... success at technology companies and expanding global markets with a special emphasis on ...
Breaking Medicine News(10 mins):Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 3Health News:24/7 Care At Home Receives Two Stars from the VA 2Health News:24/7 Care At Home Receives Two Stars from the VA 3Health News:Buckeye Health Plan Reminds Parents to Keep Immunizations In Mind As School Year Kicks Off 2Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 2Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 3Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3
... conducted by the anthropologists, from the University of Connecticut, University ... , ,They said that Neanderthals were very good in hunting ... modern humans. ,But the early modern humans ... due to the competition they received from the early modern ...
... by scientists belonging to the Northwestern University targeted at ... //The gene therapy, described in the January online issue ... Bohn and her laboratory group at Northwestern University Feinberg ... Medical Research Council Professor and director of the neurobiology ...
... on the rise and is rapidly becoming the number one cancer ... seriousness of the situation is apparent after going through recent data ... ,The rise is being documented mainly in the metros, but it ... unnoticed. It is reported that one in 22 women in India ...
... more than a couple of seconds to decide whether the ... findings. The decision is often taken in less than a ... impossible to really see anything in less than 500 milliseconds,’ ... has published the research in the journal Behavior and Information ...
... improvements made in diagnoses and treatment of the fatal ... a cure rate of 90%, according to researchers belonging ... ,The progressive improvement in the cure rate since ... reflects in large part the more effective use of ...
... to medical science, doctors under the leadership of Dr Hasan ... would perform surgery on patients while they// are in a ... out from their bodies while the surgery is being performed ... is complete. ,The return of blood would be ...
Cached Medicine News:Health News:Acute Lymphoblastic Leukemia May Attain a 90% Cure Rate 2
... Sensor is the first sensor designed specifically ... sensor is the first and only sensor ... and children. Cyanotic infants and children ... and accurate pulse oximetry, and Masimo's research ...
ELISA kit for Varicella-zoster IgG detection....
... Virus (VZV) IgG Enzyme-Linked Immunosorbent Assay (ELISA) ... determination of IgG antibody to VZV in ... be used for the determination of immune ... be used to demonstrate seroconversion or a ...
Inquire...
Medicine Products: